MDNA — Medicenna Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- CA$173.40m
- CA$151.64m
- 49
- 13
- 89
- 49
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 4.71 | 8.24 | 17.4 | 22.5 | 16.3 |
Operating Profit | -4.71 | -8.24 | -17.4 | -22.5 | -16.3 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -4.71 | -8.28 | -17.3 | -22.6 | -10 |
Net Income After Taxes | -4.71 | -8.28 | -17.3 | -22.6 | -10 |
Net Income Before Extraordinary Items | |||||
Net Income | -4.71 | -8.28 | -17.3 | -22.6 | -10 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4.71 | -8.28 | -17.3 | -22.6 | -10 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.183 | -0.259 | -0.348 | -0.416 | -0.155 |